LUCENTIS 10 MG/ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE

Ülke: Malezya

Dil: İngilizce

Kaynak: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Aktif bileşen:

Ranibizumab

Mevcut itibaren:

NOVARTIS CORPORATION (MALAYSIA) SDN. BHD.

INN (International Adı):

Ranibizumab

Paketteki üniteler:

1units Units

Tarafından üretildi:

NOVARTIS PHARMA STEIN A.G.

Bilgilendirme broşürü

_Consumer Medication Information Leaflet (RiMUP) _
LUCENTIS
®
RANIBIZUMAB
10mg/mL solution for injection in pre-filled syringe
1
WHAT IS IN THIS LEAFLET
1.
WHAT LUCENTIS IS USED FOR
2.
HOW LUCENTIS WORKS
3.
BEFORE YOU TAKE LUCENTIS
4.
HOW TO USE LUCENTIS
5.
WHILE USING LUCENTIS
6.
SIDE EFFECTS
7.
STORAGE AND DISPOSAL OF
LUCENTIS
8.
PRODUCT DESCRIPTION
9.
MANUFACTURER AND PRODUCT
REGISTRATION HOLDER
10.
DATE OF REVISION
WHAT LUCENTIS IS USED FOR
Lucentis is a solution given by
your ophthalmologist (eye doctor)
as an injection into the eye under a
local anesthetic.
Lucentis is used to treat damage to
the retina caused by growth of
leaky, abnormal blood vessels
(choroidal neovascularization,
CNV) in diseases such as:

Wet
age related macular degeneration
(wet AMD)

CNV secondary to
pathologic myopia (PM)

CNV
due to other causes, such as
angioid streaks, post-inflammatory
retinochoroidopathy, central serous
chorioretinopathy, and
inflammatory CNV

Diabetic
macular edema (DME), or edema
due to retinal vein occlusion
(RVO) where fluid accumulates
into the back of the eye.
HOW LUCENTIS WORKS
Lucentis contains the active
substance ranibizumab, which is a
part of an antibody. Antibodies are
proteins which specifically
recognise and bind to other unique
proteins in the body. Ranibizumab
binds selectively to a protein called
human vascular endothelial growth
factor A (VEGF-A), which is
present in the retina (the light-
sensitive back part of the eye).
Ranibizumab reduces both the
growth and the leakage of new
blood vessels in the eye, abnormal
processes that contribute to the
progression of wet age-related
macular degeneration (wet AMD)
or pathologic myopia (PM, a type
of severe and progressive
nearsightedness), and the
development of macular edema
(swelling) due to either diabetes
(diabetic macular edema, DME) or
retinal vein occlusion (RVO).
BEFORE YOU USE LUCENTIS
Follow all the doctor’s instructions
carefully. They may differ from
the general information contained
in this leaflet.
_When you must not use

Ürün özellikleri

Drug Regulatory Affairs
LUCENTIS 
( ranibizumab)
10 mg/mL solution for injection in pre-filled syringe
Malaysian Package Insert – (Oct 2017)
(0.165 mL volume)
IPL Author : Reema Rajaneesh
CDS Author (s): Q Luethi -Peng , T. Armstrong
GLC approval: 30 September 2014, amended 15 -Sep -2015, 10- Nov -2015,
28 -Jun -2016 and 25 -Sep -2017
Release date: 6-Oc≥ -2017
Tracking Number: Not Applicable
Document status: Final
Number of pages: 36